To date, more than 20 positive clinical trials with PEA have been presented and reviewed in detail, with a total of nearly 2000 patients treated. No side effects have been reported, nor have there been any deleterious drug interactions.23 In a recent case series of severe central neuro pathic pain in King Charles spaniels, PEA also reduced pain as well as inflammation of the eyes. This clearly supports the analgesic as well as the anti-inflammatory properties of PEA. PEA may thus represent a promising addition to our analgesic regimen for the treatment of man as well as for companion animals, with potential for good tolerability.24 For all types of Neuropathic Pain MINUS the Pain 11 12 Clinical Validation of PEA: Compelling Body of Evidence Highlighting PEA’s Activity and Tolerability in Chronic Pain >2,500 patients treated with PEA in >35 published clinical studies of PEA >1,500 patients studied in 15 RCTs ~900 patients treated with PEA Consistent, clinically meaningful reductions in pain PEA in Chronic Pain Benign tolerability profile Activity across a broad range.

Clinical Validation of PEA

Compelling Body of Evidence Highlighting PEA’s Activity

and Tolerability in Chronic Pain